Compare PHI & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PHI | MIRM |
|---|---|---|
| Founded | 1928 | 2018 |
| Country | Philippines | United States |
| Employees | 14420 | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 5.7B |
| IPO Year | N/A | 2019 |
| Metric | PHI | MIRM |
|---|---|---|
| Price | $20.70 | $91.58 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 12 |
| Target Price | N/A | ★ $115.33 |
| AVG Volume (30 Days) | 84.2K | ★ 631.6K |
| Earning Date | 05-14-2026 | 05-04-2026 |
| Dividend Yield | ★ 5.67% | N/A |
| EPS Growth | N/A | ★ 74.59 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $19,138,000.00 |
| Revenue This Year | $4.16 | $26.22 |
| Revenue Next Year | $2.56 | $22.04 |
| P/E Ratio | $10.44 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $18.61 | $40.00 |
| 52 Week High | $24.51 | $109.28 |
| Indicator | PHI | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 40.98 | 44.05 |
| Support Level | $20.47 | $85.35 |
| Resistance Level | $23.38 | $98.03 |
| Average True Range (ATR) | 0.37 | 3.22 |
| MACD | 0.07 | -0.49 |
| Stochastic Oscillator | 39.33 | 16.05 |
PLDT Inc is a telecommunications and digital services provider. The group has three reportable operating segments: Wireless, Fixed Line, and Others. Maximum revenue is generated from its Fixed Line segment, which offers fixed line telecommunications services, servicing retail, corporate, and small and medium-sized enterprises clients. The Fixed Line business segment offers data, voice, and miscellaneous services. It also offers secure data centers, multi-cloud, cybersecurity, data, and artificial intelligence (AI) solutions through different subsidiaries. The Wireless segment generates revenue by offering access to mobile internet via smartphones, mobile broadband using pocket WiFi, or home WiFi using fixed wireless broadband devices. Geographically, the group operates in the Philippines.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.